The Deadly Effects of Smoking and Secondhand Smoke

Sep.01.2022
The Deadly Effects of Smoking and Secondhand Smoke
Smoking is a leading cause of death in the US, causing chronic obstructive pulmonary disease, asthma and even diabetes. Secondhand smoke is also harmful.

If you smoke, your body will be harmed - we all know that. But did you know that being around people who smoke today can also harm your body?


Smoking is the leading cause of death in the United States. However, it is often attributed to something else medically speaking. Deaths may be attributed to chronic obstructive pulmonary disease, asthma, and even diabetes - conditions that are worsened by smoking or caused by smoking.


If you don't smoke, you are already doing the first thing you can do to prevent these terrible, but preventable diseases. The second thing you can do is to avoid second-hand smoke," said Todd Mahr, an allergist and immunologist as well as an expert on the harmful effects of smoking at the Gunderson Health System. It means that if you are exposed to second-hand smoke, you are constantly in the presence of people who are smoking.


Second-hand smoke is a bigger problem for young children. When discussing third-hand smoke with parents, they often say "I never smoke around them," but the smoke still lingers on their clothing and in the surrounding area, which can still be harmful, according to Mahr. However, there is now one thing you can do to extend your life expectancy.


He said, "Some people don't consider e-cigarettes as smoking. Being unique is important, but being unique doesn't always mean it's a good thing. People say, 'I'm vaping. All I'm inhaling is water vapor.' But in reality, they contain chemicals that can lead to cancer.


This story is part of a series by the Valley Media Group exploring the leading causes of death from 1999 to 2020. The data in this story is sourced from the Centers for Disease Control and Prevention.


The fourth leading cause of death in the area.


Chronic Lower Respiratory Disease (CLRD) encompasses Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, as well as asthma, pulmonary hypertension, and occupational lung diseases.


According to data from the Centers for Disease Control and Prevention, it is the sixth leading cause of death in the United States, responsible for 152,657 deaths.


In the valley region, 4,116 people died from CLRD in 2020, making it the fourth leading cause of death in La Crosse County, Vernon County, Dunn County, Trempealeau County, Chippewa County, and Monroe County in Wisconsin, as well as Houston County and Winona County in Minnesota.


Chronic obstructive pulmonary disease (COPD) accounts for the majority of chronic lower respiratory diseases and is primarily caused by smoking in approximately 85% of cases.


Over time, exposure to irritants in cigarette smoke can weaken the lungs' ability to resist infection, leading to tracheal inflammation and damage to air sacs or alveoli. Long-term exposure to air pollution, smoke, chemicals, or secondhand smoke also contributes to the development of chronic obstructive pulmonary disease (COPD), as does vaping e-cigarettes and smoking marijuana. Symptoms of COPD include shortness of breath, wheezing, or chronic coughing.


Chronic obstructive pulmonary disease (COPD) has decreased from being the fourth leading cause of death in the United States in 2018 to the sixth in 2020, but its incidence rate may be higher than expected.


More than 50% of adults with poor lung function are unaware that they have chronic obstructive pulmonary disease, according to a study conducted in 2013.


Dr. Hafiz Fakih, a pulmonary and critical care specialist at the Greater Los Angeles VA Healthcare System, explains that there may be a potential underreporting of deaths related to chronic obstructive pulmonary disease (COPD) due to the condition being listed as the cause of death instead of the actual underlying cause of death.


Fatal consequences


Smoking is terrible. But just how terrible is it?


Mahr states, "The most important thing is that smoking can lead to everything. We are talking about lower respiratory tract diseases, but it can lead to many illnesses and disabilities, actually harming every organ in the body.


Most Americans are aware that smoking has a significant impact on the lungs, but that's not all. According to Mahr, it affects a person's entire body.


Around 16 million Americans suffer from smoking-related diseases, including lung cancer and chronic obstructive pulmonary disease. However, smoking can also lead to or worsen heart disease, stroke, other lung diseases, diabetes, emphysema, and chronic bronchitis. It even increases the risks of tuberculosis and eye diseases and can severely damage our immune systems. From a medical standpoint, smoking can affect everything. In relation to the COVID-19 virus, smoking also increases the risk of infection.


In recent years, there has been a significant decrease in the smoking rates of adults, going from 20.9% in 2005 to 12.5% in 2020. Additionally, smoking rates among youth have dropped from 23% in 2000 to 2.3% in 2021.


According to Fakih, while the mortality rate for men suffering from chronic obstructive pulmonary disease (COPD) has decreased slightly, "the mortality rate for women with COPD is slightly higher," as the rate of female smokers declining is slower than that of men.


Race is also a factor in smoking rates - 21.9% of American Indians and Alaskan Natives smoke, as do 16.8% of African Americans and Blacks. Non-Hispanic white smokers have a slightly lower smoking rate at 16.6%, but their use of menthol cigarettes is only one-third that of African American smokers. Menthol products make smoking more enjoyable and harder to quit.


According to Fakih, we can manage the damage caused by smoking, but we cannot reverse it. When you quit smoking, the harm will come to an end.


The COVID-19 pandemic has heightened people's awareness of lung diseases. According to Mahr, it is now evident that simply wearing a mask every day is not the straightforward solution for calming lung infections and chronic illnesses.


It all depends on your personal risk factors. Respiratory illnesses are not very common, and most people would attribute them to community-acquired pneumonia and bronchitis. However, they are still fatal. Look at the statistics. Many people are struggling for their lives," Mahr said. "We know that one thing that increases your risk of disease and death is smoking. People should be aware of this. If possible, quit.


Disclaimer: 1. The content of this article is compiled from third-party information and is intended for industry exchange and learning purposes only. 2. The views expressed in this article do not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the content of the article. The compilation of this article is only for industry exchange and research purposes. 3. Due to limited compiling skills, the compiled article may not fully express the original article, please refer to the original article for accuracy. 4. 2FIRSTS fully supports the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign affairs. 5. The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Philip Morris Korea launched TEREA ONYX, a new tobacco stick line for IQOS ILUMA devices, on October 15, 2026. The initial products, AMANG PEARL and CALI PEARL, feature tropical-inspired flavors, Fresh Filters and capsules designed to deliver different flavor experiences before and after activation. Both are priced at KRW 4,800 per pack and are available at convenience stores nationwide and IQOS-operated stores in South Korea. The launch expands the Korean TEREA portfolio from four product lines to five, following earlier capsule tobacco stick additions in 2026.
product
Oct.23
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
Philip Morris International (PMI) plans to invest approximately PHP 4.5 billion ($71 million) to expand its existing smoke-free manufacturing facility in Tanauan, Batangas, in the Philippines. The expansion is expected to be completed in 2027, with additional capacity serving domestic and export markets. The facility began manufacturing heated tobacco consumables in April 2024, including BLENDS sticks for the BONDS by IQOS platform. Philippine business media reported in October 2026 that products from the Batangas plant were being exported to 18 markets across Asia and Europe. PMI says it has invested more than $2 billion in the Philippines since 2010. The expansion adds to the country's existing manufacturing and export role within PMI's international supply chain.
company
Nov.16